Abstract Details

Title Brivaracetam Monotherapy Patient Characteristics, Treatment Patterns, and Healthcare Resource Utilization Among Patients With Epilepsy: A Cohort Study Using US Claims Data

Topic Epilepsy/Clinical Neurophysiology (EEG)

Presentation(s) P12 - Poster Session 12 (11:45 AM-12:45 PM)

Poster/Presentation
Number 9-017

Objective To assess patient characteristics, treatment patterns, and epilepsy/seizure-related healthcare resource utilization (HCRU) in patients with epilepsy who initiated brivaracetam (BRV) monotherapy.

Background BRV monotherapy real-world data are limited.

Design/Methods Retrospective analysis of de-identified data from Merative MarketScan of patients with epilepsy/seizure diagnoses (ICD-9 345.X/780.39; ICD-10 G40.X/R56.9) restricted to BRV monotherapy (defined as patients with a BRV pharmacy claim [date of first BRV claim during the identification period (01/01/2016–12/31/2020) = index date], antiseizure medications [ASMs] prescribed before BRV initiation discontinued <90 days after BRV initiation, and no claim for other ASM within 90 days after BRV initiation), with medical/pharmacy benefits for 12 months before and ≥90 days after index. HCRU (hospitalizations, intensive care unit [ICU], emergency department [ED], and outpatient [OP] neurology visits) were captured 12 months before (baseline) and after first BRV prescription (follow-up; ranging from 3-12 months).

Results 594 patients (mean age 32.9 years; 56.9% female; 17.7%/79.3%/3.0% were <16/16-64/≥65 years of age) were identified. In the year before BRV initiation, 91.6% were taking ≥1 ASM (94.3%/90.9%/94.4% of patients aged <16/16-64/≥65 years); levetiracetam was the most frequent last ASM before BRV initiation (49.2%/49.0%/49.1%/52.9% of all/<16/16-64/≥65 years). 81.3% of patients had >365 days of follow-up (85.7%/80.9%/66.7% of patients aged <16/16-64/≥65 years). At 12-month follow-up, 31.5% of patients remained on BRV monotherapy (33.3%/30.6%/44.4% of patients aged <16/16-64/≥65 years). Median time to BRV discontinuation (Kaplan-Meier estimates) was 369 days (374 days/363 days for patients aged <16/16-64 years; not reached for patients ≥65 years). Epilepsy/seizure-related HCRU decreased for all/<16/16-64/≥65 groups from baseline to follow-up for hospitalizations: 15.5%/13.3%/16.1%/11.1% to 7.9%/8.6%/8.1%/0; ICU visits: 6.4%/2.9%/7.2%/5.6% to 2.5%/1.9%/2.8%/0; ED visits: 43.1%/44.8%/43.5%/22.2% to 20.5%/20.0%/21.2%/5.6%; and OP neurology visits: 70.9%/71.4%/70.7%/72.2% to 57.4%/59.0%/57.1%/55.6%.

Conclusions Approximately a third of patients in all age groups remained on BRV monotherapy at 12 months. For patients who initiated BRV monotherapy, epilepsy/seizure-related HCRU decreased from baseline to 12-month follow-up.

Authors/Disclosures
Brian D. Moseley, MD PRESENTER	Dr. Moseley has received personal compensation for serving as an employee of UCB. Dr. Moseley has received personal compensation for serving as an employee of Neurocrine Biosciences Inc. Dr. Moseley has or had stock in UCB.
Beade Numbere, PhD	Dr. Numbere has received personal compensation for serving as an employee of UCB Pharma.
Herve Besson (UCB)	Herve Besson has received personal compensation for serving as an employee of UCB.
Anna Kuba	Ms. Kuba has received personal compensation for serving as an employee of UCB.
Dimitrios Bourikas (UCB)	Dr. Bourikas has nothing to disclose.
Kristy L. Pucylowski, PharmD (UCB, Inc.)	Dr. Pucylowski has received personal compensation for serving as an employee of UCB, Inc.. Dr. Pucylowski has stock in UCB, Inc..
Allison Little, PharmD (UCB, Inc)	Dr. Little has received personal compensation for serving as an employee of Rapport Therapeutics.

��ɫ��

��ɫ��